Risk factors of development of left ventricular hypertrophy in patients with hypertensive disease with high compliance to treatment

Kardiologiya

Volumn 52, Issue 4, 2012, Pages 25-30

  Koziolova, N A ^a   Shatunova, I M ^a   Lazarev, I A ^a  

^a Gazprom Neft JSC   (Russian Federation)

Author keywords

Hypertensive disease; Left ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; VENTRICULAR REMODELING;

EID: 84866451718     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Katholi R. E., Collrt D M. Int Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. J Hypertens 2011;2011:495349.
2. Dunn E.G. Hypertension and cardiac hypertrophy. Hypertension. Frankfurt-Main: Universimed Vertag 1987:348.
3. Schillaci G., Verdecchia P., Porcellali C. et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000;35:580-586.
4. Guerra F., Mancinelli L, Angelini L. et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One 201 l;6:e16 630.
5. Sciacqua A., Miceli S., Carullo G. et al. One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 2011;34:1406-1411.
6. Izzo R., de Simone G., Devereux R.B. et al. Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension. J Hypertens 2011;29:803-808.
7. Gupta N. Karki P., Sharma S. et aL Effect of haemodynamic and metabolic predictors on echocardiographic left ventricular mass in non-diabetic hypertensive patients. Kathmandu Univ Med J (KUMJ) 2010;8:173-178.
8. Egan B.U., Zhao Y., Neal Axon R et al. US Trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.
9. Nicodème R., Albessard A., Amar J. et aL Poor blood pressure control in general practice: in search of explanations. Arch Cardiovasc Dis 2009;102:477-483.
10. Criswell T.J., Weber CA., Xu Y., Carter B.L. Eflect of self-efficacy and social support on adherence to antihypertensive drugs. Pharmacotherapy 2010;30:432-441.
11. Horne R., Clatworthy J., Hankins M.; ASCOT Investigators. High adherence and concordance within a clinical trial of antihypertensives. Chronic Illn 2010;6:243-251.
12. Welch L.K., Olson K.L., Snovi K.E. et al. Systolic blood pressure control after participation in a hypertension intervention study. Am J Manag Care 2011;17:473-478.
13. Poppe K.K., Doughty R.N., Yu CM. et al. MeRGE collaborators. Understanding differences in results from literature-based and individual patient meta-analyses: an example from meta-analyses of observational data. Int J Cardiol 2011;148:209-213.
14. Kaul S., Diamond GA. Trial and error. How to avoid commonly enCollntered limiutions of published clinical trials. J Am Coll Cardiol 2010;55:415-427.
15. Saccu L. The uncontrolled clinical trial: scientific, ethical, and practical reasons for being. Intern Emerg Med 2010;5:201-204.
16. WHO. 1999 Worid Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
17. Morisky D.E., Green L. W., Levine D.U. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24: 67-74.
18. Chobanian A. V., Bakris G.L., Black H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Conunittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:I206-1252.
19. Devereux R B., Bella J., Boman K. et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001;10:74-82.
20. Greenhalgh T., Helman C. Chowdhury A. Health beliefs and folk models of diabetes in British Bangladeshis: a qualitative study. Br Med J 1998;316:978-983.
21. Hansen D., Vach W., Roshom J. et al. Eariy discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Family Pract 2004;21:623-629.
22. Laramee A., Levinsky S., Sargent J. et al. Case management in a heterogeneous congestive heart failure population. Arch Intern Med 2003;163:809-817.
23. Piette J., Weinberger U., Kraemer F, McPhee S. Impact of automated calls with nurese follow-up on diabetes treatment outcomes in a department of veterans affairs health care system. Diabet Care 2001;24:2002-2008.
24. O'Halloran P., Gran G, Beringer T. et al. A cluster randomised controlled trial to evaluate a policy of making hip protectors available to residents of nursing homes. Age Ageing 2004;33:6:582-588.
25. Julien J., Tranche C, Souchet T. Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis. Arch Mal Coeur Vaiss 2004;97:221-227.
26. Verdecchia P., Staessen Angeli F. et al.; the Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomized trial. Lancet 2009;374:525-533.
27. Mos L, Visentin P., Zaetta V. et al. Pre-menopausal women are more prone to develop left ventricular hypertrophy than men m stage 1 hypertension. A longitudinal analysis from the HARVEST. Eur Heart J 2007;28:264-265.
28. Jullien v., Gosse P., Ansoborio P. et al. Relationship tjetween left ventricular mass and serum cholesterol level in the untreated hypertensive. J Hypertens 1998;16:1043-1047.
29. Sundstrom J., Lind L., Vessby B. el al. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circubtion 2001;103:836-841.
30. Horio T., Miyazato J., Kamide K. et al. Influence of low high-density Apoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 2003; 16:938-944.
31. de las Fuentes L., Soto P.P., Cupps B.P. et al. Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol 2006;13:369-377.
32. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004,261:187-191.
33. Schmieder R.E., Kjeldsen S.E, Julius S. et al. Detenninants of the new development of left ventricular hypertrophy on treated hypertensives: The VALUE-trial. J Hypertens 2004;22:S277.
34. Garzp C, Pellikka P., Somers V. et al. Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for mortjid obesity. Am J Cardiol 2010;105:550-556.
35. Rider O.J., Francis J.M., All M.K. et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol 2009;54:718-726.